Antidepressant monotherapy: A claims database analysis of treatment changes and treatment duration

Miléa, D.; Guelfucci, F; Bent‐Ennakhil, Nawal; Toumi, Mondher; Auray, Jean-Paul

doi:10.1016/j.clinthera.2010.11.011

Cited by 52 publications

(71 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because TBZ depletes DA, a logical point of focus was on an antidepressant that works on DA, such as the catecholamine uptake inhibitor bupropion (Wellbutrin). Bupropion is one of the most widely prescribed antidepressants [63], and it is one of the few antidepressants that has shown efficacy in treating the effort-related symptoms such as fatigue, anergia and psychomotor retardation in patients with depression and related disorders [44], [46], [64]–[66]. In the current experiments, bupropion was capable of reversing the effects of TBZ on the PROG/chow procedure, increasing total lever presses, highest ratio achieved and active lever time.…”

Section: Discussionmentioning

confidence: 48%

The VMAT-2 Inhibitor Tetrabenazine Affects Effort-Related Decision Making in a Progressive Ratio/Chow Feeding Choice Task: Reversal with Antidepressant Drugs

et al. 2014

View full text Add to dashboard Cite

Behavioral activation is a fundamental feature of motivation, and organisms frequently make effort-related decisions based upon evaluations of reinforcement value and response costs. Furthermore, people with major depression and other disorders often show anergia, psychomotor retardation, fatigue, and alterations in effort-related decision making. Tasks measuring effort-based decision making can be used as animal models of the motivational symptoms of depression, and the present studies characterized the effort-related effects of the vesicular monoamine transport (VMAT-2) inhibitor tetrabenazine. Tetrabenazine induces depressive symptoms in humans, and also preferentially depletes dopamine (DA). Rats were assessed using a concurrent progressive ratio (PROG)/chow feeding task, in which they can either lever press on a PROG schedule for preferred high-carbohydrate food, or approach and consume a less-preferred lab chow that is freely available in the chamber. Previous work has shown that the DA antagonist haloperidol reduced PROG work output on this task, but did not reduce chow intake, effects that differed substantially from those of reinforcer devaluation or appetite suppressant drugs. The present work demonstrated that tetrabenazine produced an effort-related shift in responding on the PROG/chow procedure, reducing lever presses, highest ratio achieved and time spent responding, but not reducing chow intake. Similar effects were produced by administration of the subtype selective DA antagonists ecopipam (D1) and eticlopride (D2), but not by the cannabinoid CB1 receptor neutral antagonist and putative appetite suppressant AM 4413, which suppressed both lever pressing and chow intake. The adenosine A2A antagonist MSX-3, the antidepressant and catecholamine uptake inhibitor bupropion, and the MAO-B inhibitor deprenyl, all reversed the impairments induced by tetrabenazine. This work demonstrates the potential utility of the PROG/chow procedure as a rodent model of the effort-related deficits observed in depressed patients.

show abstract

Section: Discussionmentioning

confidence: 48%

The VMAT-2 Inhibitor Tetrabenazine Affects Effort-Related Decision Making in a Progressive Ratio/Chow Feeding Choice Task: Reversal with Antidepressant Drugs

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Early discontinuation of antidepressants among diagnosed patients has also been reported [6, 10–14]. Modifications, such as switching or combining different antidepressants, have been shown to seldom occur [9, 11, 14, 15]. In many countries, however, increased use of antidepressants during the last two decades has been accompanied by decreased suicide rates [16, 17].…”

Section: Introductionmentioning

confidence: 99%

Antidepressant use in suicides: a case-control study from the Friuli Venezia Giulia Region, Italy, 2005–2014

Castelpietra

Gobbato²,

Valent³

et al. 2017

Eur J Clin Pharmacol

View full text Add to dashboard Cite

PurposeTo compare the use of antidepressant (AD) classes and compounds in individuals who committed suicide and in controls from the general population and to assess to what extent adherence and current use of different AD classes can affect the risk of committing suicide.MethodsIndividual data on suicide, diagnoses and AD use in Friuli Venezia Giulia from 2005 to 2014 were obtained from the Regional Social and Health Information System. All suicides that had at least one prescription of AD in the 730 days before death (N = 876) were included as cases. Each case was matched with regard to age and sex with five controls from the general population. The association between suicide and AD use was assessed using conditional logistic regression analysis.ResultsAlmost 70% of all suicides occurring in the10-year period had been prescribed AD. Selective serotonin reuptake inhibitors (SSRIs) accounted for more than the 90% of the prescriptions, with paroxetine the most prescribed AD. All AD compounds and classes were not associated with a higher suicide risk, with the exception of SSRI (OR = 1.6). A decreasing trend in suicide risk was observed when adherent subjects or current AD users were compared to the others.ConclusionsAD treatment is an important factor for preventing suicide, since the use of AD at adequate dosage and for a proper duration was associated with a lower suicide risk. The proper use of AD should be ascertained by physicians, particularly in a primary care context.Electronic supplementary materialThe online version of this article (doi:10.1007/s00228-017-2236-0) contains supplementary material, which is available to authorized users.

show abstract

“…1Y3 Up to one third of patients with MDD may require a change in treatment plan. In retrospective database studies, 13% to 23% of patients with depression switched to a different antidepressant or received augmentation of their initial antidepressant treatment within a year of their index prescription 6,7 ; in the STAR*D trial, 1439 (39%) of 3671 patients who started therapy were enrolled in subsequent (step 2) treatments because they did not achieve remission or could not tolerate their first treatment step. 8 During the second STAR*D treatment step, 21% of patients who switched drugs and 30% of patients who had treatment augmented subsequently achieved remission.…”

mentioning

confidence: 99%

Early Improvement in Depressive Symptoms With Desvenlafaxine 50 mg/d as a Predictor of Treatment Success in Patients With Major Depressive Disorder

Soares¹,

Fayyad²,

Guico-Pabia³

2014

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

Antidepressant monotherapy: A claims database analysis of treatment changes and treatment duration

Cited by 52 publications

References 43 publications

The VMAT-2 Inhibitor Tetrabenazine Affects Effort-Related Decision Making in a Progressive Ratio/Chow Feeding Choice Task: Reversal with Antidepressant Drugs

The VMAT-2 Inhibitor Tetrabenazine Affects Effort-Related Decision Making in a Progressive Ratio/Chow Feeding Choice Task: Reversal with Antidepressant Drugs

Antidepressant use in suicides: a case-control study from the Friuli Venezia Giulia Region, Italy, 2005–2014

Early Improvement in Depressive Symptoms With Desvenlafaxine 50 mg/d as a Predictor of Treatment Success in Patients With Major Depressive Disorder

Contact Info

Product

Resources

About